SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
South Plains Financial terminated a Board Representation Agreement with Henry TAW LP, a shareholder that originally owned approximately 16% and now owns less than 10% of outstanding shares. The termination reflects the Company's maturation as a public entity and shift toward a broader shareholder base.
View raw filing on EDGAR →South Plains Financial entered into a stock repurchase agreement with retiring CEO Curtis C. Griffith to repurchase 300,000 shares at fair market value, approved by the board with Griffith recused. The repurchase is a related-party transaction tied to his retirement.
View raw filing on EDGAR →Bed Bath & Beyond entered into a Merger Agreement and Plan of Reorganization with Fathom Holdings Inc. on June 16, 2026, whereby Fathom will merge with a wholly owned subsidiary of the Company, with Fathom surviving as a subsidiary of Bed Bath & Beyond. This is a material acquisition involving an exchange ratio of 0.2236 shares of Company Common Stock per FTHM share, subject to customary closing conditions and stockholder approval. The transaction is clearly a material change of control requiring Item 1.01 disclosure.
View raw filing on EDGAR →The filing discloses a merger transaction between Sila Realty Trust and Sunshine Ultimate Parent LLC, with a special stockholder meeting scheduled for June 26, 2026 to approve the merger. The Item 8.01 disclosure supplements the proxy statement with updated financial advisor analyses and background information regarding the merger process, including contact with 81 potential buyers. This is a material acquisition/change of control event that would significantly affect investor assessment of the registrant.
View raw filing on EDGAR →Michael McCormick was appointed Chief Executive Officer and President of Nuwellis, Inc., effective June 30, 2026, and elected to the Board. John L. Erb transitioned from CEO to Chairman. McCormick brings extensive executive experience in medical device companies.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of Mastercard's June 16, 2026 annual meeting of stockholders, including votes on director elections (11 nominees), advisory approval of executive compensation, ratification of PricewaterhouseCoopers LLP as auditor, and two shareholder proposals. The detailed vote tallies (For, Against, Abstain, Broker Non-Votes) for each matter are the core content, making this a textbook shareholder_vote_results event that is material to investors assessing board composition and governance outcomes.
View raw filing on EDGAR →CarMax issued a press release on June 17, 2026, announcing first quarter financial results for the period.
View raw filing on EDGAR →CarMax entered into a $500 million term loan credit agreement with MUFG Bank on June 15, 2026, establishing a three-year term facility with customary covenants and interest terms.
View raw filing on EDGAR →This exhibit is a formal report from TSX Trust Company documenting the results of Aura Minerals' Annual General and Special Meeting of Shareholders held on June 16, 2026. It discloses voting outcomes on director elections (Paulo de Brito, Bruno Mauad, Pedro Turqueto, Richmond Fenn, Stephen Keith, and Paulo de Brito Filho), auditor appointment, and amendment/restatement of the company's memorandum and articles of association, with specific vote tallies and percentages for each matter. This is a classic shareholder_vote_results disclosure.
View raw filing on EDGAR →The 6-K discloses a grant of options under the "Foundation Plan for Growth" to 12 PDMRs (persons discharging managerial responsibilities), including the CEO, CFO, and other named executives. The announcement details the vesting conditions (50% after three years, 50% after four years, subject to TSR performance), exercise prices, and aggregate grant values (totaling approximately €109.8 million across all recipients). This is a material compensatory arrangement affecting senior executives' equity interests, falling squarely within exec_compensation disclosure requirements under Market Abuse Regulation 596/2014.
View raw filing on EDGAR →The primary disclosed action is the appointment of Will Fuller as President and Chief Operating Officer of Aegon, effective January 1, 2027. Fuller will assume responsibility for day-to-day management of Transamerica, International businesses, and Asset Management, reporting to CEO Lard Friese. This is a material executive appointment at a major financial services holding company, affecting the group's operational leadership structure during a critical strategic transition (redomiciliation to the United States).
View raw filing on EDGAR →The 6-K body contains a press release announcing Deswell's second half and full year fiscal 2026 financial results (for the year ended March 31, 2026), including net sales of $61.3 million, net income of $10.6 million, and earnings per share of $0.67. The disclosure also announces a regular cash dividend of $0.10 per share and a special cash dividend of $0.20 per share. This is a discrete earnings announcement with detailed financial statements and MD&A, not a periodic report filing itself.
View raw filing on EDGAR →Board report addressing shareholder approval of the renewal and restatement of the Company's authorised capital to EUR 100 million and the Board's authority to limit or suppress preferential subscription rights in future capital increases, presenting material implications for capital structure flexibility and potential shareholder dilution.
View raw filing on EDGAR →Susan Reisbord has been appointed President & Chief Executive Officer, effective October 1, 2026, representing a material change in the company's top executive leadership. While Gord Johnston's retirement as CEO is also disclosed, the principal action is Reisbord's appointment to the CEO role. The press release emphasizes this as a Board-led succession plan with continuity, and Reisbord's appointment would materially affect investor assessment of the company's leadership and strategic direction.
View raw filing on EDGAR →This exhibit is a formal Report of Voting Results from Satellos Bioscience Inc.'s annual shareholder meeting held June 17, 2026. It discloses the outcomes of two matters voted upon: (1) election of nine directors with detailed vote tallies for each nominee, and (2) appointment of PricewaterhouseCoopers LLP as auditor with 98.69% approval. This is a classic shareholder_vote_results disclosure required under National Instrument 51-102 and material to investors assessing board composition and auditor appointment.
View raw filing on EDGAR →The exhibit discloses equity compensation grants to directors, officers, employees, and consultants: 201,969 stock options at $2.30 per share and 266,035 restricted share units, approved by the Board on June 11, 2026, with three-year vesting schedules. While the press release also announces receipt of a $50,000 government grant for exploration (operational/financial), the substantive disclosure requiring classification under 8-K Item 5.02(e) standards is the equity award grant, which is material to investors assessing management incentive alignment and potential dilution.
View raw filing on EDGAR →HDFC Bank Limited has completed the issuance of USD 750 million senior unsecured bonds with a 5-year tenure (maturity June 24, 2031) and a coupon of 5.067% per annum. This is a material creation of a direct financial obligation disclosed under SEBI Listing Regulations Regulation 30, constituting a significant debt issuance that would affect a reasonable investor's assessment of the registrant's capital structure and financial position.
View raw filing on EDGAR →The 6-K discloses results of an extraordinary general meeting of shareholders held on June 17, 2026, where shareholders voted on and approved the election of two Standing Directors (Baek, Woo-Ki and Chun, Chan-Hyuk) and two Non-Standing Audit Committee Members (Jung, Do-Jin and Hwang, Jeong-Hwa), with detailed voting tallies showing approval percentages ranging from 97.4% to 99.1%. This is a classic shareholder_vote_results disclosure under Item 5.07 equivalent, and director elections are material governance events affecting the composition of the board.
View raw filing on EDGAR →This is a press release announcing 17EdTech's unaudited financial results for the first quarter of 2026, dated June 17, 2026. The exhibit discloses quarterly net revenues of RMB99.5 million (up 359% year-over-year), gross margin of 61.9%, and net loss of RMB19.4 million (down 37.4% year-over-year), along with detailed operating expense breakdowns and cash position. The disclosure includes management commentary and is accompanied by unaudited condensed consolidated financial statements and reconciliations of non-GAAP measures. This is a discrete earnings announcement, not a periodic financial report filing, and the results are material to investors assessing the company's operational performance and financial trajectory.
View raw filing on EDGAR →The 6-K discloses the final results of the 2026 Annual Meeting of Shareholders held on June 15, 2026, specifically the election of six directors (Michael Cricenti, Bo Hu, Peter R. Kellogg, Ruigang Li, Tao Wang, and Chunhua Yu) with detailed vote tallies showing shares for, against, abstained, and broker non-votes for each candidate. This is a classic shareholder_vote_results disclosure under Item 5.07 equivalent, and board composition is material to investors.
View raw filing on EDGAR →NOVONIX announced a material capital raising comprising an institutional placement of 129,334,163 ordinary shares at A$0.16 per share (a 31.2–33.3% discount to market prices) under ASX Listing Rule 7.1 placement capacity, together with a non-underwritten share purchase plan (SPP) offering up to 18,750,000 shares to eligible shareholders at the same price. The placement and SPP are expected to raise approximately A$23.7 million in aggregate, directed toward capital expenditure and production capacity expansion.
View raw filing on EDGAR →MagnaChip held its Annual Meeting on June 11, 2026, with shareholders voting on four proposals: election of four directors, advisory vote on named executive officer compensation, ratification of auditor EY Han Young, and approval of the Amended and Restated 2020 Equity and Incentive Compensation Plan. Final vote tallies and percentages for each proposal are disclosed.
View raw filing on EDGAR →This exhibit discloses comprehensive changes to Toyota's board of directors and executive structure effective June 17, 2026, including the appointment of Kenta Kon as President and Representative Director, Hiroki Nakajima and Yoichi Miyazaki as Executive Vice Presidents, and the transition of Koji Sato from Vice Chairman to a continued Vice Chairman role. The document also details organizational restructuring and CxO assignments. While multiple individual executive appointments occur, the disclosure is fundamentally a governance restructuring announcement that would materially affect investor assessment of leadership and strategic direction, warranting classification as a material governance event rather than discrete appointment/departure events.
View raw filing on EDGAR →Daniel J. Thoren, Executive Chairman and director, notified the Company on June 15, 2026 of his intention to step down from both positions effective immediately, with transition arrangements and continued compensation as a Strategic Advisor.
View raw filing on EDGAR →Jonathan W. Painter was appointed as Chairman of the Board of Directors, effective June 17, 2026, as disclosed in a press release accompanying the filing.
View raw filing on EDGAR →The disclosure announces completion of target enrollment in a Phase 2b clinical trial (MIST trial) for AP01, a lead product candidate. While this is a material clinical development milestone that would affect investor assessment of the company's pipeline progress and de-risking, it does not fit neatly into the standard taxonomy categories. The event is disclosed under Item 7.01 (Regulation FD Disclosure) rather than a dedicated Item, and represents clinical trial progress rather than earnings, M&A, executive changes, or other specifically enumerated event types.
View raw filing on EDGAR →The filing discloses a press release under Item 8.01 (Other Events) but provides no substantive detail about the content or nature of the announcement. Without access to Exhibit 99.1, the specific event cannot be determined. Given Verizon's size and the formal 8-K filing, the press release likely addresses a material matter, but the event type cannot be confidently classified without knowing its subject matter.
View raw filing on EDGAR →Smartbird amended its Securities Purchase Agreement to increase the aggregate principal amount of senior secured convertible notes from $50.0 million to $100.0 million, with conversion into Class A common stock at $4.00 per share, representing a material dilutive issuance of convertible securities.
View raw filing on EDGAR →Nadia Carlsten was appointed as President, Chief Executive Officer, Secretary, and director of Smartbird, Inc., effective June 18, 2026, bringing expertise in AI and advanced computing. The appointment included a substantial inducement grant of 1,532,379 RSUs outside the Company's stockholder-approved equity plan.
View raw filing on EDGAR →Smartbird amended its Certificate of Incorporation and Bylaws to change the company name to Smartbird, Inc., remove public benefit corporation status, and lower the stockholder quorum requirement from a majority to one-third, representing material governance and structural changes.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from Shift4 Payments' Annual Meeting of Stockholders held on June 12, 2026, covering five proposals: election of three Class III directors (Sam Bakhshandehpour, Jonathan Halkyard, and Nancy Disman), ratification of PricewaterhouseCoopers LLP as auditor, advisory approval of named executive officer compensation, approval of an amended certificate of incorporation, and approval of the 2026 Employee Stock Purchase Plan. The filing presents detailed vote tallies for each proposal and confirms all items passed, which is material to investors' understanding of corporate governance and shareholder sentiment.
View raw filing on EDGAR →Lynne C. Fitzpatrick has been appointed as Chief Executive Officer of CME Group, effective on the later of March 1, 2027, or the 2026 10-K filing date, succeeding Terrence A. Duffy. Duffy will transition to Executive Chairman, and compensatory arrangements have been established for both executives as part of the planned succession.
View raw filing on EDGAR →AstroNova entered into an Agreement and Plan of Merger on June 16, 2026, whereby Orion Merger Parent, Inc. (affiliated with Arcline Investment Management LP) will acquire the Company for $29.00 per share in cash. The transaction is subject to shareholder approval and regulatory clearance under the HSR Act, with customary termination rights and a $9.648 million termination fee.
View raw filing on EDGAR →Harmonic completed the sale of its Video Business to Leone Media Inc. (MediaKind) for $145 million in cash on June 16, 2026, pursuant to a previously disclosed Asset Purchase Agreement.
View raw filing on EDGAR →Neven Haltmayer, Senior Vice President and General Manager of the Video Business, resigned effective June 16, 2026, after 20 years of service, in connection with the completion of the Video Business sale.
View raw filing on EDGAR →Boyd Group Services Inc. announced a cash dividend of C$0.156 per common share for Q2 2026, payable July 29, 2026 to shareholders of record on June 30, 2026. This is a straightforward dividend declaration, which is a material capital allocation event that affects shareholder value and is routinely disclosed in 6-K filings by foreign private issuers.
View raw filing on EDGAR →This 8-K Item 5.07 discloses the final results of votes at Boundless Bio's annual stockholder meeting held June 15, 2026, covering two proposals: election of Class II directors (James Christensen and Jennifer Lew) and ratification of KPMG LLP as independent auditor. The tabulated vote counts for each proposal are the core disclosure required under Item 5.07, making this a textbook shareholder vote results filing that is material to investors assessing board composition and audit oversight.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure of shareholder meeting results. The filing reports voting outcomes on four proposals at the 2026 Annual Meeting held June 17, 2026: election of two Class III directors (Michael Landsittel and Cameron Turtle), Say-on-Pay advisory vote, Say-on-Frequency advisory vote, and auditor ratification. All proposals passed with strong majorities, and the Board determined to hold annual Say-on-Pay votes based on the voting results.
View raw filing on EDGAR →The filing discloses a notice of delinquency from NYSE Regulation on May 19, 2026, for failure to timely file the Form 10-Q, triggering Section 1007 procedures and subjecting the Company to potential suspension and delisting. Although the Company subsequently filed the Form 10-Q on June 12, 2026, and regained compliance by June 15, 2026, the core event disclosed under Item 3.01 is the delisting risk and the Company's path through the compliance remediation process. This is material to investors as it reflects a serious breach of listing standards and the threat of delisting, even though the immediate risk was cured before the 8-K filing date.
View raw filing on EDGAR →This 8-K Item 5.07 discloses the certified results of Alector's 2026 annual meeting of stockholders held on June 17, 2026, including voting outcomes for three proposals: election of Class II directors (Elizabeth Garofalo, Errol De Souza, and Kristine Yaffe), ratification of Ernst & Young LLP as independent auditor, and advisory approval of named executive officer compensation. The filing presents vote tallies (for, against, abstentions, broker non-votes) for each matter, which is the core disclosure required under Item 5.07 for shareholder meeting results.
View raw filing on EDGAR →Outset Medical entered into a material amendment to its purchasing agreement with HCA on June 14, 2026, committing HCA to purchase approximately $40 million in new Tablo Hemodialysis Systems from 2026 through 2028, representing a significant multi-year commercial commitment affecting the company's revenue pipeline.
View raw filing on EDGAR →Item 2.02 disclosure explicitly references a press release issued on June 17, 2026, and states that textual information from that press release is being furnished in connection with "Results of Operations and Financial Condition." This is the standard format for earnings release disclosures under Item 2.02, with the press release attached as Exhibit 99.1.
View raw filing on EDGAR →ImageneBio held its Annual Meeting on June 16, 2026, with shareholders voting on three proposals: election of two Class II directors (David P. Bonita and Joseph P. Slattery), ratification of PricewaterhouseCoopers LLP as independent auditor, and approval of the 2025 Amended Equity Incentive Plan.
View raw filing on EDGAR →The Company entered into an underwriting agreement on June 15, 2026, to offer and sell 14,000,000 shares of common stock through a forward sale mechanism, with an additional 2,100,000 shares subject to an underwriter option. This is a material equity issuance that will dilute existing shareholders. Although structured as a forward sale (with settlement expected by June 16, 2027), the Company will receive net proceeds and contribute them to its operating partnership for acquisitions and general corporate purposes, making this a dilutive capital raise transaction.
View raw filing on EDGAR →Stacey Moser was appointed as Chief Customer Officer, with the appointment announced on June 17, 2026 as part of organizational changes. The appointment is accompanied by a comprehensive compensation package including $500,000 in RSU equity awards and $500,000 in cash retention awards with specific vesting schedules and severance acceleration provisions.
View raw filing on EDGAR →Allurion Technologies implemented a 1-for-15 reverse stock split, approved by stockholders at the December 2025 Annual Meeting, with the Charter Amendment filed on June 12, 2026 and effective June 17-18, 2026. This material corporate action affects the company's share structure, trading symbol, and terms of warrants and convertible securities.
View raw filing on EDGAR →The Company resubmitted a New Drug Application (NDA) to the FDA for relacorilant, a treatment for Cushing's syndrome. This is a material regulatory milestone for a biopharmaceutical company, as NDA resubmission represents progress toward potential commercialization of a key product candidate. However, it does not fit neatly into the more specific event categories (e.g., it is not an earnings release, M&A activity, or executive change), making "other_material" the most appropriate classification.
View raw filing on EDGAR →The Company entered into a Third Amended and Restated Operating Agreement on June 15, 2026, which amended the operating agreement to reflect the liquidation and dissolution of Series I and updated indemnification provisions. This represents a material structural change to the Company's organizational documents and governance framework.
View raw filing on EDGAR →Fiserv entered into an Underwriting Agreement on June 16, 2026, to issue €1 billion in senior notes (€500M due 2030 at 3.750% and €500M due 2034 at 4.250%) in a public offering expected to close June 23, 2026. While this is a debt issuance rather than a traditional M&A transaction, Item 1.01 ("Entry into a Material Definitive Agreement") captures material financing arrangements. The €1 billion aggregate principal amount and the formal underwriting structure with major investment banks (Citigroup, J.P. Morgan, TD, Wells Fargo) indicate materiality to investors assessing the company's capital structure and liquidity.
View raw filing on EDGAR →The filing discloses Odyssey Therapeutics' financial results for the three months ended March 31, 2026, with a press release furnished as Exhibit 99.1. This is a standard quarterly earnings announcement under Item 2.02, which is the designated Item for disclosure of results of operations and financial condition.
View raw filing on EDGAR →